SCHEMBL1133671

SCHEMBL1133671

O=C(O)C(Cc1ccccc1)N1C(=O)C(=Cc2ccc(-c3ccc(OC(F)(F)F)cc3)s2)NC1=S

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.42
▸ BCL2 P10415 4/20 0.42
▸ BCL2L2 Q92843 4/20 0.42
▸ BAD Q92934 4/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ CRHBP P24387 1/20 0.42
▸ CRHR2 Q13324 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ADAMTS5 Q9UNA0 1/20 0.39
▸ PRF1 P14222 7/20 0.39
▸ POLB P06746 2/20 0.39
▸ CTSL P07711 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ PTPN1 P18031 1/20 0.38
▸ PLA2G1B P04054 1/20 0.38
▸ ATG4B Q9Y4P1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4380180 1.00 MAPT (0.42) MAPTBCL2BCL2L2BADMEN1
SCHEMBL13587014 0.89 MAPT (0.54) MAPTBCL2BCL2L2BADMEN1
SCHEMBL4374614 0.89 MAPT (0.54) MAPTBCL2BCL2L2BADMEN1
SCHEMBL1134035 0.89 MAPT (0.54) MAPTBCL2BCL2L2BADMEN1
SCHEMBL1133612 0.88 PRF1 (0.49) MAPTBCL2BCL2L2BADMEN1
SCHEMBL13587021 0.88 PRF1 (0.49) MAPTBCL2BCL2L2BADMEN1
SCHEMBL1133613 0.88 PRF1 (0.49) MAPTBCL2BCL2L2BADMEN1
SCHEMBL1133776 0.86 PRF1 (0.49) MAPTBCL2BCL2L2BADMEN1
SCHEMBL1133775 0.86 PRF1 (0.49) MAPTBCL2BCL2L2BADMEN1
SCHEMBL13587022 0.86 PRF1 (0.49) MAPTBCL2BCL2L2BADMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2285802-B1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY ASTEX PHARMACEUTICALS INC (US) 2015-11-11 — — EP disclosed
US-8759384-B2 Oxo-imidazolyl compounds ASTEXPHRMACEUTICALS, INC. 2014-06-24 — — US disclosed
EP-2285802-A1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY SuperGen, Inc. (US) 2011-02-23 — — EP disclosed
US-20090298900-A1 Oxo-Imidazolyl Compounds ASTEXPHRMACEUTICALS, INC. 2009-12-03 — — US disclosed
WO-2009139870-A1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY SUPERGEN, INC. 2009-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298900-A1 Oxo-Imidazolyl Compounds GALE, CYP51A1, GNE MAPT 4793/4885BCL2 3457/4885BCL2L2 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback